Current & Past Research

Building the evidence, one study at a time.

Research spans several connected focus areas, developed by allergists and researchers connected to the FAIT Program at UBC and BC Children's Hospital.

CAN-FAIT Registry

Almost 2,500 patients, and growing.

Founded in 2017 as CPP-OIT, the registry now holds data spanning most Canadian provinces, plus international collaborators in Hong Kong, Denmark and the United Arab Emirates.

0 patients in the registry

Active studies

FAIT Program

The FAIT Program is a UBC / BC Children's Hospital research program developing and delivering real-world food allergy treatments for BC families. It is a 100% virtual, nurse-led program. Participants are invited to join the CAN-FAIT Registry. To be eligible, a child must be a current patient at the BC Children's Hospital allergy clinic.

CAN-FAIT Research Collaboration and Registry

Founded in 2017 (originally "CPP-OIT") to develop and implement peanut oral immunotherapy protocols in real patients outside of clinical trials. The registry began with a small group of preschoolers and now holds data on almost 2,500 patients and growing, covering peanut, tree nut, sesame and other food allergies. Members now represent most Canadian provinces, plus international collaborators in Hong Kong, Denmark and the United Arab Emirates.

IMPAACT Clinical Validation Study

Impairment Measure for Parental Food Allergy-Associated Anxiety and Coping Tool — validating a new screening questionnaire for food-allergy-associated anxiety at the BC Children's Hospital Allergy Clinic.

Electronic consent form →

FAIT Biobanking Study

FAIT Program patients at UBC/BCCH are invited to contribute blood samples to the FAIT Biobank, building a resource for future food allergy research.

DINOSAUR

Deep phenotypINg Of infantS And toddlers Undergoing food oral immunotheRapy. Examines factors in a child before and after OIT — compared against a waitlist group — to understand which factors predict a successful course of treatment.

Clinical Trials

The BC Children's Hospital allergy clinic is a trial site for new food allergy treatments, including the DBV Technologies peanut patch trials (Pepites, PEOPLE, Realise, EPITOPE, VITESSE) and the ALK Abello ALLIANCE peanut sublingual tablet trial, plus the RAPT trial led by Dr. Raymond Mak.

Publications

Peer-reviewed research from the collaboration

Twelve publications so far, spanning safety, effectiveness and real-world protocols for oral and sublingual immunotherapy.

Soller L, Abrams EM, Carr S, et al. First real-world safety analysis of preschool peanut oral immunotherapy. JACI: In Practice 2019; 7(8): 2759-2767.e5. Read →
Soller L, Abrams EM, Carr S, et al. First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy. JACI: In Practice 2021; 9(3): 1349-1356. Read →
Soller L, Carr S, Kapur S, et al. Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective. JACI: In Practice 2022; 10(4):1113-1116. Read →
Chua G, Greenhawt M, Shaker M, et al. The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention. JACI: In Practice 2022; 10(10): 2561-2569. Read →
Chua G, Greenhawt M, Shaker M, et al. Real-world data are critical for the implementation of preschool food allergen immunotherapy. JACI In Practice 2023; 11(8): 2624-2625. Read →
Chua G, Chan E, Invik R, et al. How We Manage Gastrointestinal Symptoms During Oral Immunotherapy Through a Shared Decision-Making Process. JACI: In Practice 2023; 11(4): 1049-1055. Read →
Karunakaran D, Chan ES, Zhang Q, et al. Risk factors associated with safety of preschool peanut oral immunotherapy. JACI: Global 2023; 2(2). Read →
Erdle S, Cook V, Cameron S, et al. Real-world Safety Analysis of Preschool Tree Nut Oral Immunotherapy. JACI: In Practice 2023; 11(4): 1177-1183. Read →
Soller L, Williams BA, Mak R, et al. Safety and Effectiveness of Bypassing Oral Immunotherapy Buildup With an Initial Phase of Sublingual Immunotherapy for Higher-Risk Food Allergy. JACI: In Practice 2024; 12(5): 1283-1296. Read →
Chua G, Soller L, Kapur S, et al. Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy. JACI: Global 2024; 3(1). Read →
Williams BA, Guo Y, Soller L, Chan ES, Pratap-Singh A. Total protein content and in vitro protein penetration rates of sublingual immunotherapy preparations. Annals of Allergy, Asthma & Immunology 2024; 133(6):723-735. Read →
Williams BA, Baaske A, Soller L, et al. The use of grocery-sourced real-food solutions in sublingual immunotherapy for food allergies. Annals of Allergy, Asthma & Immunology 2025; 135(1): 79-86. Read →

Interested in research collaboration?

Reach out with questions about the registry, protocols, or partnering with the Network.

Ask About Research or Collaboration →